Press Release
<< Back
Verastem to Present Data at the 2015 American Association of Cancer Research Annual Meeting
The details for the data presentations at AACR are as follows:
|
Oral Presentations |
|
Title: FAK inhibitors VS-6063 and VS-4718 target cancer stem cells: Implications for TNBC sequential and combination therapies |
|
Date and time: Sunday, April 19, 2015, 3:20 pm – 3:35 pm ET |
|
Location: Room 115 |
|
Abstract number: 974 |
|
Session info: Session Title: Cancer Stem Cells 1; Session Category: Tumor Biology; Session Type: Minisymposium |
|
Title: Efficacy of focal adhesion kinase inhibition in IKZF1-altered BCR-ABL1 acute lymphoblastic leukemia |
|
Date and time: Tuesday, April 21, 2015, 4:05 pm – 4:20 pm ET |
|
Location: Room 120 |
|
Abstract Number: 4732 |
|
Session info: Session Title: Pediatric Cancer: Basic Science 3; Session Category: Tumor Biology; Session Type: Minisymposium |
|
Poster Presentations |
|
Title: FAK and PI3K/mTOR inhibitors target cancer stem cells: Implications for SCLC treatment strategies |
|
Date and time: Monday, April 20, 2015, 8:00 am – 12:00 pm ET |
|
Location: Section 19; Poster Board 24 |
|
Abstract Number: 1525 |
|
Session info: Session Title: Solid Tumor Stem Cells; Session Category: Tumor Biology |
|
Title: FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells, which are enriched by standard of care chemotherapy |
|
Date and time: Tuesday, April 21, 2015, 1:00 pm – 5:00 pm ET |
|
Location: Section 21; Poster Board 23 |
|
Abstract Number: 4236 |
|
Session info: Session Title: Therapeutics Targeting Cancer Stem Cells; Session Category: Tumor Biology |
|
Title: Targeting Focal Adhesion Kinase is a novel approach to therapy of high-risk, Ikaros-mutant acute B-cell lymphoblastic leukemia |
|
Date and time: Tuesday, April 21, 2015, 1:00 pm – 5:00 pm ET |
|
Location: Section 20; Poster Board 17 |
|
Abstract Number: 4202 |
|
Session info: Session Title: Mouse Models of Human Cancer 3; Session Category: Tumor Biology |
About VS-6063
VS-6063 (defactinib) is an orally available compound designed to target
cancer stem cells through the potent inhibition of focal adhesion kinase
(FAK). Cancer stem cells are an underlying cause of tumor resistance to
chemotherapy, recurrence and ultimate disease progression. Research by
About VS-4718
VS-4718 is an orally available compound designed to target cancer stem cells through the potent inhibition of focal adhesion kinase (FAK). VS-4718 is currently being studied in a Phase 1 dose escalation study in patients with advanced cancers.
About VS-5584
VS-5584 is an orally available compound that has demonstrated potent and
highly selective activity against class 1 PI3K enzymes and dual
inhibitory actions against mTORC1 and mTORC2. In preclinical studies,
VS-5584 has been shown to reduce the percentage of cancer stem cells and
induce tumor regression in chemotherapy-resistant models.
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development and activity of the Company’s product
candidates, VS-6063, VS-4718 and VS-5584, and the Company’s FAK,
PI3K/mTOR and diagnostics programs generally, and potential indications
for development of the Company’s product candidates. The words
“anticipate,” “appear,” “believe,” “estimate,” “expect,” “intend,”
“may,” “plan,” “predict,” “project,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement. Applicable risks and uncertainties include
the risks that the preclinical testing of the Company’s product
candidates and preliminary or interim data from clinical trials may not
be predictive of the results or success of ongoing or later clinical
trials, that our product candidates will cause unexpected safety events,
that the Company will be unable to successfully initiate or complete the
clinical development of its product candidates, that the development of
the Company’s product candidates will take longer or cost more than
planned, and that the Company’s product candidates will not receive
regulatory approval or become commercially successful products. Other
risks and uncertainties include those identified under the heading “Risk
Factors” in the Company’s Annual Report on Form 10-K for the year ended
Source:
Verastem, Inc.
Brian Sullivan, 781-292-4214
bsullivan@verastem.com
